Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".

Dean J. Kereiakes(Lindner Center of HOPE), Mauricio G. Cohen(Santa Ana College), Lawrence A. Barr, Rose Lengerich, David J. Moliterno(University of Kentucky), George W. Christy, Thomas Shimshak, Bruce R. Brodie(European Society of Cardiology), William Matthai, Paul N. Casale, Alan Niederman, E Fry, J P Zidar, Thomas M. Broderick

PubMed

February 1, 2000

Cited by 43

Related Papers

Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association

|Circulation|2017|1.8k

American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy

|Journal of the American College of Cardiology|2003|1.6k

2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization

|Journal of the American College of Cardiology|2021|1.5k

Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

|New England Journal of Medicine|2011|755

Predictive Factors, Management, and Clinical Outcomes of Coronary Obstruction Following Transcatheter Aortic Valve Implantation

|Journal of the American College of Cardiology|2013|643